The Role of Glial Glutamate Transporter Glt-1 Over-expression in Mitigating Visceral Nociception
Year: 2010
Type: article
Abstract: Visceral pain is the most common reason forphysician visits in US. However, the etiology of visceral
hypersensitivity is not clear. Neither is the effective therapy
available to relief visceral pain. Glutamate is the major
excitatory neurotransmitter and mediates aspects of visceral
hypersensitivity. Rapid removal of glutamate from synapse is
predominantly mediated by glial glutamate transporter-1 (GLT-1),
thus terminating the glutamate stimulation. GLT-1 is found
down-regulated in the neuropathic injury model and the artificial
induction of GLT-1 attenuates neuropathic pain. In this
dissertation, the role of GLT-1 induction in visceral nociception
is investigated. Genetic and pharmacological
approaches were utilized to establish GLT-1 induction. In the
transgenic mice model, GLT-1 transgene was driven by glial
fibrillary acidic protein (GFAP) and over-expressed in astrocyte
cells in central nervous system. In the pharmacological model,
expression of GLT-1 was enhanced by intraperitoneal administration
of ceftriaxone (CTX). Transgenic animals
overexpressing GLT-1 significantly reduced visceral nociceptive
responses. In consistent, one week administration of ceftriaxone
reduced the visceromotor response (VMR) to colorectal distention
(CRD). In addition, this inhibition of visceral nociception could
be blocked by systematic treatment with dihydrokainate (DHK), a
selective GLT-1 inhibitor. This data indicates that enhanced
glutamate reuptake attenuates colorectal distention-induced
visceral nociception.Further study showed that intrathecal delivery
of GLT-1 antagonist DHK to the lumbar spinal cord dose-dependently
reversed CTX-blunted visceral nociceptive response, whereas
intracisternal delivery of DHK failed to produce visceral
anti-nociceptive effects, suggesting a role of spinally located
glutamate transporter GLT-1 in visceral nociception. In addition,
one-week CTX treatment exhibited no effect on somatic sensory and
motor function. This data indicated that GLT-1 upregulation by CTX
treatment mitigates visceral nociception through spinal mechanisms.
The role of GLT-1 in animal models of colitis
was then investigated. One week CTX treatment upregulated the
expression of GLT-1 and reversed the TNBS-induced visceral
hypersensitivity. In addition, CTX treatment one week after the
onset of DSS-induced visceral inflammation could also attenuate the
visceral nociceptive response, suggesting a potential therapeutic
effect of CTX. Further experiment revealed that CTX treatment
reduced inflammation in the TNBS-induced colitis, but not in DSS
model. Cephalothin, another antibiotic lacking GLT-1 induction
ability, demonstrated the efficiency to inhibit inflammation but
failed to block visceral hypersensitivity, suggesting that GLT-1
over-expression mitigates visceral inflammatory nociception.
Taken together, these studies indicated that
GLT-1 over-expression is a novel and effective method to attenuate
visceral nociception.
Author: Yuan Lin
Institution: The Ohio State University
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2236417794
